Drug Trial Radar · NCT01435759
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,197
Actual
Start
May 31, 2011
Primary completion
Jan 17, 2014
Study completion Jan 17, 2014
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can SPD489 help patients with depression who are also taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Conditions
- Major Depressive Disorder
Interventions
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mgDrug
Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mgDrug
Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mgDrug
Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mgDrug
Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
Antidepressant + PlaceboDrug
oral, once daily for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)Time frame: Augmentation Baseline (Week 8) to Week 16
Locations
82 sites in 5 countries. Site status is shown where the registry gives one.
Arkansas Psychiatric Clinic Clinical Research Trials
Little Rock, Arkansas
South Coast Clinical Trials
Anaheim, California
Catalina Research Institute, LLC
Chino, California
Shanti Clinical Trials
Colton, California
Clinical Innovation, Inc.
Costa Mesa, California
Collaborative Neuroscience Network, Inc.
Garden Grove, California
Irvine Center for Clinical Research
Irvine, California
Omega Clinical Trials
La Habra, California
Provate Practice of Andrew Leuchter, MD
Los Angeles, California
PCSD - Feighner Research
San Diego, California
Artemis Institute for Clinical Research
San Diego, California
Neuropsychiatric Research Center of Orange County
Santa Ana, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
Western Affiliated Research Institute
Denver, Colorado
Connecticut Clinical Research
Cromwell, Connecticut
Institute of Living
Hartford, Connecticut
The Hospital of Central Connecticut, Psychiatry & Behavioral Health Research
New Britain, Connecticut
Gulfcoast Clinical Research Center
Fort Myers, Florida
Sarkis Clinical Trials
Gainesville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Private Practice - Amit Vijapura MD
Jacksonville, Florida
Psychiatric Associates
Lake City, Florida
Comprehensive Neuroscience, Inc.
Miramar, Florida
Fideltiy Clinical Research, Inc.
North Miami, Florida
Ali A. Kashfi, MD, PA
Orlando, Florida
Clinical Research of Central Florida
Winter Haven, Florida
Kolin Research Group
Winter Park, Florida
Institute for Behavioral Medicine, LLC
Smyrna, Georgia
Treatment Research Center, Rush University Medical Center
Chicago, Illinois
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois
Psychiatric Medicine Associates, LLC
Skokie, Illinois
Sleep and Behavior Medicine Institute
Vernon Hills, Illinois
Clinical Trials Technology, Inc.
Prairie Village, Kansas
Pedia Research, LLC
Owensboro, Kentucky
Psyichatric Care and Research Center
O'Fallon, Missouri
Mid-America Clinical Research, LLC
St Louis, Missouri
Premier Psychiatric Research Institute, LLC.
Lincoln, Nebraska
Clinical Research Consortium
Las Vegas, Nevada
Center for Emotional Fitness
Cherry Hill, New Jersey
CRI Worldwide LLC
Willingboro, New Jersey
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.